10-Q: NewAmsterdam Pharma Q1 2026 Results: Obicetrapib Trials Progress

NewAmsterdam Pharma reports Q1 2026 results with ongoing clinical trials for obicetrapib, a potential LDL-C lowering therapy, and European regulatory reviews progressing.

Summary

• NewAmsterdam Pharma reported its financial results for the first quarter ended March 31, 2026.
• The company continues to advance its late-stage biopharmaceutical development, focusing on obicetrapib for cardiometabolic diseases.
• Phase 3 trials for obicetrapib (monotherapy and combination with ezetimibe) have met primary and secondary endpoints, with additional data expected in 2026.
• Marketing Authorization Applications (MAAs) for obicetrapib in Europe are under review, with decisions anticipated in the second half of 2026.
• The company reported a net loss of $48.4 million for the quarter, compared to a net loss of $39.5 million in the prior year period.
• Cash, cash equivalents, and marketable securities stood at $707.3 million as of March 31, 2026, providing sufficient liquidity.
• The PREVAIL cardiovascular outcomes trial (CVOT) is undergoing an interim analysis in Q4 2026, with results expected in Q1 2027.
• Exploration into obicetrapib's potential in Alzheimer's disease and diabetes is ongoing, with new trials planned.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic filing, with significant clinical trial progress and strong liquidity, but tempered by continued net losses and the inherent uncertainties of drug development and regulatory approval.

Positives

• Successful completion of Phase 3 trials (BROADWAY, BROOKLYN, TANDEM) for obicetrapib, meeting primary and secondary endpoints for LDL-C lowering.
• European MAAs for obicetrapib accepted for review, with potential launch in late 2026 in Germany and the UK.
• Strong liquidity position with $707.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
• Obicetrapib has demonstrated good tolerability in over 3,500 patients across clinical trials.
• Exploratory MACE endpoint reduction of 21% observed in the Phase 3 BROADWAY trial.
• Preclinical and early clinical evaluations for Alzheimer's disease are progressing, with a new trial expected in 2026.
• The company has a partnership with Menarini for commercialization in Europe.

Negatives

• Net loss of $48.4 million for the three months ended March 31, 2026, an increase from $39.5 million in the prior year period.
• Research and development expenses remain significant at $38.0 million for the quarter.
• The PREVAIL CVOT interim analysis results are not expected until Q1 2027, and the trial completion is anticipated by the end of 2027.
• The company has a history of losses and expects to continue incurring significant losses.
• The fair value of derivative warrant liabilities was $50.2 million as of March 31, 2026.
• Potential for significant future capital requirements.

Risks

• The topline and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification procedures.
• The PREVAIL CVOT interim analysis may not detect a statistically significant treatment benefit, or the trial could be stopped for futility.
• Current and future legislation and executive actions affecting the healthcare industry, including the Inflation Reduction Act (IRA), may impact pricing, reimbursement, and profitability.
• Regulatory reviews and approvals in Europe and the US are subject to uncertainty and timelines.
• The company's future success is highly dependent on the successful development and commercialization of obicetrapib.
• The company has limited experience in marketing or distributing products.
• The company relies on third parties for manufacturing of its product candidates.
• Potential for significant future capital requirements and the ability to secure additional capital.
• The value of derivative warrant liabilities is directly correlated to the market price of the company's Ordinary Shares.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future as it advances its product candidates through clinical trials and pursues regulatory approval. Additional capital will likely be required. The company anticipates announcing additional clinical data from Phase 3 trials in 2026 and expects decisions on European MAAs in the second half of 2026, with potential launches in late 2026. The PREVAIL CVOT interim analysis is expected in Q4 2026, with results in Q1 2027, and trial completion by end of 2027 if not stopped early. A new clinical trial for Alzheimer's disease is expected to initiate in 2026.

Management Comments

• We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved.
• We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved.
• We believe that CETP inhibition may also play a role in other indications by potentially mitigating the risk of developing diseases such as Alzheimers disease (AD).
• We estimate that in the United States there are approximately 30 million patients that are not at their risk-based LDL-C goals despite treatment with lipid lowering therapy, including approximately 13 million with ASCVD.
• Our goal is to develop and commercialize an LDL-C lowering monotherapy and an FDC therapy, which offers the advantage of a single, low dose, once-daily oral pill, and fulfills the significant unmet need for an effective and convenient LDL-C lowering therapy.
• We expect our selling, general and administrative expenses will increase due to the general growth of the organization associated with administering ongoing and planned clinical trials and our focus on commercial preparedness.

Industry Context

StockSavvy.ai notes that NewAmsterdam Pharma operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on cardiometabolic diseases. The company's progress with obicetrapib, a CETP inhibitor, aligns with industry efforts to find novel therapies for lowering LDL-C, addressing a significant unmet medical need. The ongoing regulatory reviews in Europe and the planned US submission are critical milestones. The company's reliance on clinical trial outcomes and future capital raises are typical challenges for companies at this stage.

Comparison to Industry Standards

• The company's net loss of $48.4 million for the quarter is consistent with early-stage biopharmaceutical companies investing heavily in R&D, where significant losses are common before product commercialization.
• The cash burn rate, reflected in the net cash used in operating activities of $30.6 million for the quarter, is within the range expected for companies conducting late-stage clinical trials.
• The company's strategy of pursuing both monotherapy and fixed-dose combination therapies for obicetrapib is a common approach in the pharmaceutical industry to maximize market potential and address diverse patient needs.
• The partnership with Menarini for European commercialization is a standard industry practice to leverage local market expertise and reduce upfront commercialization costs for the developing company.

Legal Proceedings

• The company is not party to any material pending legal proceedings.

Related Party Transactions

• In the ordinary course of business, the Company may enter into transactions with entities that are associated with a party that meets the criteria of a related party of the Company. These transactions are reviewed quarterly and to date have not been material to the Company's consolidated financial statements.

Stakeholder Impact

• Shareholders: Continued investment required due to ongoing losses; potential upside from successful drug development and commercialization; share price volatility influenced by clinical trial results and market conditions.
• Employees: Continued employment opportunities in a growing biopharmaceutical company; potential for equity-based compensation.
• Creditors: No significant debt disclosed, primary funding through equity and licensing agreements.
• Partners (Menarini): Progress in regulatory reviews and potential for future commercialization of licensed products.
• Patients: Potential future access to novel therapies for cardiometabolic diseases and potentially Alzheimer's disease.

Next Steps

• Announce additional clinical data from Phase 3 trials (BROADWAY, TANDEM, BROOKLYN) during 2026.
• Receive decisions on European MAAs from regulators in the second half of 2026.
• Potential launch of products in Germany and the UK in Q4 2026, if MAAs are approved.
• Conduct an interim analysis of the PREVAIL CVOT in Q4 2026.
• Initiate a new clinical trial evaluating obicetrapib in patients with early Alzheimer's disease in 2026.
• Complete the PREVAIL trial by the end of 2027, if not stopped early by the DSMB.
• Submit a New Drug Application (NDA) in the U.S. for obicetrapib as a monotherapy and for the FDC shortly thereafter.

Key Dates

Recommendation

The company shows promising clinical development and a strong liquidity position, but the path to profitability is long and uncertain, with significant reliance on regulatory approvals and future market uptake. Continued monitoring of clinical trial data, regulatory decisions, and financing activities is warranted before considering a stronger recommendation.

Keywords

NewAmsterdam Pharma, Obicetrapib, Cardiometabolic Diseases, LDL-C, CETP Inhibitor, Clinical Trials, Phase 3, SEC Filing, 10-Q, Biopharmaceutical, Menarini, European MAA, CVOT, Alzheimer's Disease